Loading…
Anti-Prothrombin Antibodies and the Lupus Anticoagulant
The investigators have evaluated the frequency and manifestations of anti-prothrombin antibodies in patients with the lupus anticoagulant. Thirty-one of 42 patients with lupus anticoagulants associated with a variety of underlying conditions (74%) had evidence on crossed immunoelectrophoresis of ant...
Saved in:
Published in: | Blood 1988-08, Vol.72 (2), p.512-519 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c494t-19c4ea3f9830775ca02c22729f05ffea02cdd0778a2a94921b79791e27f279543 |
---|---|
cites | |
container_end_page | 519 |
container_issue | 2 |
container_start_page | 512 |
container_title | Blood |
container_volume | 72 |
creator | Fleck, Rebecca A. Rapaport, Samuel I. Rao, L. Vijaya Mohan |
description | The investigators have evaluated the frequency and manifestations of anti-prothrombin antibodies in patients with the lupus anticoagulant. Thirty-one of 42 patients with lupus anticoagulants associated with a variety of underlying conditions (74%) had evidence on crossed immunoelectrophoresis of anti-prothrombin antibodies. Twenty-four of 25 patients with an activated partial thromboplastin time exceeding 50 seconds and 14 of 15 patients with a prothrombin time exceeding control by more than two seconds had demonstrable anti-prothrombin antibodies. Three of the 31 patients with anti-prothrombin antibodies had essentially no measurable plasma prothrombin, a presumed result of accelerated clearance of prothrombin/ prothrombin antibody complexes. Each of these patients had bled abnormally. The remaining patients with antiprothrombin antibodies had neither substantial hypoprothrombinemia nor hemorrhagic manifestations, which confirms the non-neutralizing property of anti-prothrombin antibodies associated with the lupus anticoagulant. Since lupus anticoagulant immunoglobulins are known to react with phospholipids, the high prevalence of antibodies binding prothrombin led us to test the hypothesis of antibody polyreactivity. Adsorption of three lupus anticoagulant plasmas with insolubilized prothrombin markedly diminished evidence of both prothrombin/prothrombin antibody complexes and anticoagulant activity. Eluates of the insolubilized prothrombin contained IgG that not only bound prothrombin but possessed lupus anticoagulant activity. © 1988 by Grune & Stratton, Inc. |
doi_str_mv | 10.1182/blood.V72.2.512.512 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78347324</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497120810258</els_id><sourcerecordid>78347324</sourcerecordid><originalsourceid>FETCH-LOGICAL-c494t-19c4ea3f9830775ca02c22729f05ffea02cdd0778a2a94921b79791e27f279543</originalsourceid><addsrcrecordid>eNp9kD9PwzAQxS0EKqXwCRBSBsSWYl-cOh4Yqop_UiUYgNVyHJsaJXGxEyS-PU4bdWQ4nc7v3fnph9AlwXNCCrgta-eq-QeDOcxzsqsjNCU5FCnGgI_RFGO8SCln5BSdhfCFMaEZ5BM0AZovGGdTxJZtZ9NX77qNd01p22R4KF1ldUhkWyXdRifrftuHnaCc_Oxr2Xbn6MTIOuiLsc_Q-8P92-opXb88Pq-W61RRTruUcEW1zAwvMsxYriQGBcCAG5wbo4exqqJSSJCcciBlTMWJBmaA8ZxmM3Szv7v17rvXoRONDUrXMYN2fRCsyCjLYDBme6PyLgSvjdh620j_KwgWAy6xwyUiLgEiohoqbl2N5_uy0dVhZ-QT9etRl0HJ2njZKhsONsZY_L6Itru9TUcUP1Z7EZTVrdKV9Vp1onL23xh_5WmHjw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78347324</pqid></control><display><type>article</type><title>Anti-Prothrombin Antibodies and the Lupus Anticoagulant</title><source>ScienceDirect Journals</source><creator>Fleck, Rebecca A. ; Rapaport, Samuel I. ; Rao, L. Vijaya Mohan</creator><creatorcontrib>Fleck, Rebecca A. ; Rapaport, Samuel I. ; Rao, L. Vijaya Mohan</creatorcontrib><description>The investigators have evaluated the frequency and manifestations of anti-prothrombin antibodies in patients with the lupus anticoagulant. Thirty-one of 42 patients with lupus anticoagulants associated with a variety of underlying conditions (74%) had evidence on crossed immunoelectrophoresis of anti-prothrombin antibodies. Twenty-four of 25 patients with an activated partial thromboplastin time exceeding 50 seconds and 14 of 15 patients with a prothrombin time exceeding control by more than two seconds had demonstrable anti-prothrombin antibodies. Three of the 31 patients with anti-prothrombin antibodies had essentially no measurable plasma prothrombin, a presumed result of accelerated clearance of prothrombin/ prothrombin antibody complexes. Each of these patients had bled abnormally. The remaining patients with antiprothrombin antibodies had neither substantial hypoprothrombinemia nor hemorrhagic manifestations, which confirms the non-neutralizing property of anti-prothrombin antibodies associated with the lupus anticoagulant. Since lupus anticoagulant immunoglobulins are known to react with phospholipids, the high prevalence of antibodies binding prothrombin led us to test the hypothesis of antibody polyreactivity. Adsorption of three lupus anticoagulant plasmas with insolubilized prothrombin markedly diminished evidence of both prothrombin/prothrombin antibody complexes and anticoagulant activity. Eluates of the insolubilized prothrombin contained IgG that not only bound prothrombin but possessed lupus anticoagulant activity. © 1988 by Grune & Stratton, Inc.</description><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood.V72.2.512.512</identifier><identifier>PMID: 2456797</identifier><language>eng</language><publisher>Washington, DC: Elsevier Inc</publisher><subject>Antibody Specificity ; Autoantibodies - analysis ; Biological and medical sciences ; Blood Coagulation Factors - analysis ; Blood Coagulation Factors - immunology ; Counterimmunoelectrophoresis ; Epitopes - analysis ; Hematologic and hematopoietic diseases ; Humans ; Lupus Coagulation Inhibitor ; Lupus Erythematosus, Systemic - immunology ; Medical sciences ; Platelet diseases and coagulopathies ; Prothrombin - immunology ; Prothrombin Time</subject><ispartof>Blood, 1988-08, Vol.72 (2), p.512-519</ispartof><rights>1988 American Society of Hematology</rights><rights>1988 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c494t-19c4ea3f9830775ca02c22729f05ffea02cdd0778a2a94921b79791e27f279543</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0006497120810258$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3549,27924,27925,45780</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=7773478$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2456797$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fleck, Rebecca A.</creatorcontrib><creatorcontrib>Rapaport, Samuel I.</creatorcontrib><creatorcontrib>Rao, L. Vijaya Mohan</creatorcontrib><title>Anti-Prothrombin Antibodies and the Lupus Anticoagulant</title><title>Blood</title><addtitle>Blood</addtitle><description>The investigators have evaluated the frequency and manifestations of anti-prothrombin antibodies in patients with the lupus anticoagulant. Thirty-one of 42 patients with lupus anticoagulants associated with a variety of underlying conditions (74%) had evidence on crossed immunoelectrophoresis of anti-prothrombin antibodies. Twenty-four of 25 patients with an activated partial thromboplastin time exceeding 50 seconds and 14 of 15 patients with a prothrombin time exceeding control by more than two seconds had demonstrable anti-prothrombin antibodies. Three of the 31 patients with anti-prothrombin antibodies had essentially no measurable plasma prothrombin, a presumed result of accelerated clearance of prothrombin/ prothrombin antibody complexes. Each of these patients had bled abnormally. The remaining patients with antiprothrombin antibodies had neither substantial hypoprothrombinemia nor hemorrhagic manifestations, which confirms the non-neutralizing property of anti-prothrombin antibodies associated with the lupus anticoagulant. Since lupus anticoagulant immunoglobulins are known to react with phospholipids, the high prevalence of antibodies binding prothrombin led us to test the hypothesis of antibody polyreactivity. Adsorption of three lupus anticoagulant plasmas with insolubilized prothrombin markedly diminished evidence of both prothrombin/prothrombin antibody complexes and anticoagulant activity. Eluates of the insolubilized prothrombin contained IgG that not only bound prothrombin but possessed lupus anticoagulant activity. © 1988 by Grune & Stratton, Inc.</description><subject>Antibody Specificity</subject><subject>Autoantibodies - analysis</subject><subject>Biological and medical sciences</subject><subject>Blood Coagulation Factors - analysis</subject><subject>Blood Coagulation Factors - immunology</subject><subject>Counterimmunoelectrophoresis</subject><subject>Epitopes - analysis</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Lupus Coagulation Inhibitor</subject><subject>Lupus Erythematosus, Systemic - immunology</subject><subject>Medical sciences</subject><subject>Platelet diseases and coagulopathies</subject><subject>Prothrombin - immunology</subject><subject>Prothrombin Time</subject><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1988</creationdate><recordtype>article</recordtype><recordid>eNp9kD9PwzAQxS0EKqXwCRBSBsSWYl-cOh4Yqop_UiUYgNVyHJsaJXGxEyS-PU4bdWQ4nc7v3fnph9AlwXNCCrgta-eq-QeDOcxzsqsjNCU5FCnGgI_RFGO8SCln5BSdhfCFMaEZ5BM0AZovGGdTxJZtZ9NX77qNd01p22R4KF1ldUhkWyXdRifrftuHnaCc_Oxr2Xbn6MTIOuiLsc_Q-8P92-opXb88Pq-W61RRTruUcEW1zAwvMsxYriQGBcCAG5wbo4exqqJSSJCcciBlTMWJBmaA8ZxmM3Szv7v17rvXoRONDUrXMYN2fRCsyCjLYDBme6PyLgSvjdh620j_KwgWAy6xwyUiLgEiohoqbl2N5_uy0dVhZ-QT9etRl0HJ2njZKhsONsZY_L6Itru9TUcUP1Z7EZTVrdKV9Vp1onL23xh_5WmHjw</recordid><startdate>19880801</startdate><enddate>19880801</enddate><creator>Fleck, Rebecca A.</creator><creator>Rapaport, Samuel I.</creator><creator>Rao, L. Vijaya Mohan</creator><general>Elsevier Inc</general><general>The Americain Society of Hematology</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19880801</creationdate><title>Anti-Prothrombin Antibodies and the Lupus Anticoagulant</title><author>Fleck, Rebecca A. ; Rapaport, Samuel I. ; Rao, L. Vijaya Mohan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c494t-19c4ea3f9830775ca02c22729f05ffea02cdd0778a2a94921b79791e27f279543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1988</creationdate><topic>Antibody Specificity</topic><topic>Autoantibodies - analysis</topic><topic>Biological and medical sciences</topic><topic>Blood Coagulation Factors - analysis</topic><topic>Blood Coagulation Factors - immunology</topic><topic>Counterimmunoelectrophoresis</topic><topic>Epitopes - analysis</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Lupus Coagulation Inhibitor</topic><topic>Lupus Erythematosus, Systemic - immunology</topic><topic>Medical sciences</topic><topic>Platelet diseases and coagulopathies</topic><topic>Prothrombin - immunology</topic><topic>Prothrombin Time</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fleck, Rebecca A.</creatorcontrib><creatorcontrib>Rapaport, Samuel I.</creatorcontrib><creatorcontrib>Rao, L. Vijaya Mohan</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fleck, Rebecca A.</au><au>Rapaport, Samuel I.</au><au>Rao, L. Vijaya Mohan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti-Prothrombin Antibodies and the Lupus Anticoagulant</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>1988-08-01</date><risdate>1988</risdate><volume>72</volume><issue>2</issue><spage>512</spage><epage>519</epage><pages>512-519</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><abstract>The investigators have evaluated the frequency and manifestations of anti-prothrombin antibodies in patients with the lupus anticoagulant. Thirty-one of 42 patients with lupus anticoagulants associated with a variety of underlying conditions (74%) had evidence on crossed immunoelectrophoresis of anti-prothrombin antibodies. Twenty-four of 25 patients with an activated partial thromboplastin time exceeding 50 seconds and 14 of 15 patients with a prothrombin time exceeding control by more than two seconds had demonstrable anti-prothrombin antibodies. Three of the 31 patients with anti-prothrombin antibodies had essentially no measurable plasma prothrombin, a presumed result of accelerated clearance of prothrombin/ prothrombin antibody complexes. Each of these patients had bled abnormally. The remaining patients with antiprothrombin antibodies had neither substantial hypoprothrombinemia nor hemorrhagic manifestations, which confirms the non-neutralizing property of anti-prothrombin antibodies associated with the lupus anticoagulant. Since lupus anticoagulant immunoglobulins are known to react with phospholipids, the high prevalence of antibodies binding prothrombin led us to test the hypothesis of antibody polyreactivity. Adsorption of three lupus anticoagulant plasmas with insolubilized prothrombin markedly diminished evidence of both prothrombin/prothrombin antibody complexes and anticoagulant activity. Eluates of the insolubilized prothrombin contained IgG that not only bound prothrombin but possessed lupus anticoagulant activity. © 1988 by Grune & Stratton, Inc.</abstract><cop>Washington, DC</cop><pub>Elsevier Inc</pub><pmid>2456797</pmid><doi>10.1182/blood.V72.2.512.512</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0006-4971 |
ispartof | Blood, 1988-08, Vol.72 (2), p.512-519 |
issn | 0006-4971 1528-0020 |
language | eng |
recordid | cdi_proquest_miscellaneous_78347324 |
source | ScienceDirect Journals |
subjects | Antibody Specificity Autoantibodies - analysis Biological and medical sciences Blood Coagulation Factors - analysis Blood Coagulation Factors - immunology Counterimmunoelectrophoresis Epitopes - analysis Hematologic and hematopoietic diseases Humans Lupus Coagulation Inhibitor Lupus Erythematosus, Systemic - immunology Medical sciences Platelet diseases and coagulopathies Prothrombin - immunology Prothrombin Time |
title | Anti-Prothrombin Antibodies and the Lupus Anticoagulant |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T15%3A04%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti-Prothrombin%20Antibodies%20and%20the%20Lupus%20Anticoagulant&rft.jtitle=Blood&rft.au=Fleck,%20Rebecca%20A.&rft.date=1988-08-01&rft.volume=72&rft.issue=2&rft.spage=512&rft.epage=519&rft.pages=512-519&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood.V72.2.512.512&rft_dat=%3Cproquest_cross%3E78347324%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c494t-19c4ea3f9830775ca02c22729f05ffea02cdd0778a2a94921b79791e27f279543%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=78347324&rft_id=info:pmid/2456797&rfr_iscdi=true |